Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03556007 · ClinicalTrials.gov registry record · Phase 1

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

A Phase 1 study, sponsored by Nektar Therapeutics.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT03556007: Completed Phase 1 study, sponsored by Nektar Therapeutics.

NCT03556007 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03556007, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.

Primary Outcome

Safety and tolerability of LY3471851 as assessed through collection of adverse events, serious adverse events, change in vital signs (body temperature, blood pressure, heart rate, rate of breathing and oxygen in blood); electrocardiograms (ECG); laboratory evaluations (hematology, chemistry, liver function and urine analysis).

Interventions

  • DRUG Placebo
  • DRUG LY3471851

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2018-04-18
Est. Completion 2019-08-29
Phase Phase 1
Nektar Therapeutics

37 total trials

What the finished NCT03556007 record still lists

NCT03556007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03556007 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03556007 about?

NCT03556007 is a clinical study titled "A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)". The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.

What is the current status of trial NCT03556007?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-04-18. Estimated completion is 2019-08-29.

What interventions are being tested in trial NCT03556007?

The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).

Who is sponsoring clinical trial NCT03556007?

This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03556007's enrollment target sits among peer trials

48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03556007, the US trial registry maintained by the National Library of Medicine. NCT03556007 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.